Project Grant R01AI188944
Award Date 8/8/25
Completion Date 7/31/30
Dollars Obligated $575K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $884,453 Project Grant to Brigham & Women's Hospital Inc. to develop a rapid, cost-effective point-of-care (POC) diagnostic test for Hepatitis C Virus (HCV) detection. The 5-year project, which commenced on November 22, 2024, aims to create a highly sensitive and specific HCV antigen (Ag) testing solution that can streamline...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $272,133 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Rutgers, The State University of New Jersey to develop a rapid antigen test for diagnosing active hepatitis C virus (HCV) infection. The goal is to create a low-cost, instrument-free test that can accelerate diagnosis and linkage to care, as current treatments can effectively cure HCV but most infected...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $776,341 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois on September 16, 2025. The purpose of this grant is to develop a microfluidic cartridge, molecular biology method, biosensor, and detection instrument that can simultaneously detect HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) viral loads from a minimal 100 μL whole blood sample. This...
- The U.S. Centers for Disease Control and Prevention (CDC) awarded a $233,666 Project Grant to Esper Biosciences Inc. in Ithaca, NY on September 30, 2025 under the CDC Investigations and Technical Assistance program (CFDA 93.283). The grant funding supports the development of a rapid point-of-care nucleic acid test for Hepatitis C using nanosensors. This project aligns with the CDC program's goals of controlling communicable diseases and developing innovative health technologies. The award has...
- This Project Grant award, totaling $354,570.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop a cost-effective and user-friendly point-of-care (POC) diagnostic tool, employing a novel "CamoChip" technology, for highly sensitive and multiplex testing of biomarkers related to HIV/HBV co-infection. The key products and services to be delivered under...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $972,583 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Research Institute at Nationwide Children's Hospital in Ohio. The grant, titled "Defining Successful Intrahepatic CD4+ T Cell Responses Against the Hepatitis C Virus," aims to study protective CD4+ T cell responses in order to develop an effective vaccine against chronic Hepatitis C virus (HCV) infection....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $806,208 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Weill Medical College of Cornell University. The project, titled "Spatial Omics to Understanding HBV Control in People with HIV Coinfection," will leverage cutting-edge spatial proteomic and transcriptomic technologies to analyze the impact of HIV-related immune suppression and restoration on the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $5,504,270 Cooperative Agreement to The Johns Hopkins University on September 26, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The award will establish a multinational cohort of people with HIV and chronic hepatitis B (PWHHB) to apply novel technologies and advance a hepatitis B virus (HBV) functional cure. The project aims to characterize mechanisms of intrahepatic HBV...
- The federal Project Grant award of $231,552 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the role of intrahepatic (liver-resident) plasma cells in clearing hepatitis C virus (HCV) infection. The project aims to determine the mechanistic origins of these liver-resident plasma cells during acute HepaCViral infection, with the goal of identifying specific prerequisites...
- This $814,790 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to uncover the immune mechanisms underlying hepatitis B virus (HBV) surface antigen clearance, which can lead to a clinical cure for chronic HBV infection. The principal investigators at the University of California, San Francisco (UCSF) will leverage mouse models and clinical samples from HBV patients to conduct a...